An update on Direct Oral Anticoagulant (DOAC) use in venous thromboembolism. Preliminary results from the COBRRA study where apixaban and rivaroxaban were compared head-to-head will be discussed, as well as recommendations from the 2025 Australian guidelines, including guidance on laboratory testing, perioperative and bleeding management.